Xlife Sciences AG
🇨ðŸ‡XSWX.XLSSwitzerlandHealthcare
PriceCHFÂ 10.30-1.00 (-8.85%)
Latest anomalies
Neutral 0 detected in the last 120 days
- High: 0
- Medium: 0
- Low: 0
No anomaly detected for this instrument.
Free with a Finzer account.
Profile
- Healthcare
- Biotechnology
- Switzerland
Identity
- Exchange
- SIX Swiss Exchange . XSWX
- Type
- Stock
- ISIN
- CH0461929603
- CUSIP
- Not reported
Company
- Employees
- 17
- Headquarters
- Zurich, Switzerland
- Website
- https://www.xlifesciences.ch
Market
- Shares outstanding
- 5.8M
- Market cap
- CHFÂ 59.41M
Highlights
- Market cap
- CHFÂ 59.41M
- EPS LTM
- Not reported
- P/E LTM
- Not reported
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- Not reported
- Net income
- Not reported
- Gross margin
- Not reported
- Free cash flow
- Not reported
Latest news
News is not sourced for this exchange.
Business summary
Xlife Sciences AG is a company in the healthcare sector, listed on SIX Swiss Exchange (Switzerland) under the ticker XLS. Its market capitalisation is CHFÂ 59.41M, from 5.8M shares outstanding, as of . Across the 249 trading sessions to the shares traded between CHFÂ 10.30 and CHFÂ 26.80, and the last close of CHFÂ 10.30 sits 0% of the way up that range. The company is headquartered in Zurich, Switzerland, and employs about 17 people.
Xlife Sciences AG focuses on the development and commercialization of research projects in the life sciences sector. The company's project covers technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health areas that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data. It also produces, researches, develops, and manufactures the chemical and active pharmaceutical ingredients for human and veterinary medicines; and offers clinical research organization services. In addition, the company builds a bridge between research/ development and healthcare markets, as well as support researchers and entrepreneurs in the positioning, structuring, development, and implementation of their ideas; and operates as an active ingredient manufacturer. Further, it focuses on identifying innovative biomarkers in the field of kidney diseases; the development of antibody-drug conjugates through a click chemistry approach and microfluidic screening of functional antibodies; and provides Neuromex, a screening instrument for the early-stage detection of neurological diseases. Xlife Sciences AG was founded in 2019 and is headquartered in Zurich, Switzerland.